Global News Distribution

TREATMENT

US Veterans and Injured Workers Find Injury Solution With sam® Sustained Acoustic Medicine Treatment

May 11, 2022 (Global News Distribution) -

Innovative medical technologies like the sam® device promote soft tissue healing

Sustained acoustic medicine, or sam®, is a non-invasive ultrasound device from ZetrOZ Systems used to treat soft tissue injuries and arthritis. The U.S. Federal Drug Administration cleared sam® for clinical use in 2013, but many health care providers are just now discovering the many benefits it provides to treatment and recovery efforts.

The sam® pain relief device has helped thousands of patients, including U.S. Veterans and Active Duty Members, regain mobility and reduce pain from common overuse injuries and osteoarthritis. “Sam has been a wonderful medical device to represent in our region since the benefit to patients is tremendous, the product is made in the USA, and the clinical outcomes are clear,” says Mr. Harmon, President of a well-established & long-time distributor for ZetrOZ Systems. “We have no other medical device that can help patients heal faster and reduce the need for surgery and opioids.”

ZetrOZ is driven by innovation, and the sam® pain relief technology is clinically proven to augment the body’s natural ability to heal. “We have been offering sustained acoustic medicine (sam®) since 2016. We have helped countless patients restore function and reduce narcotic and opioid use thanks to sam®. It is truly unique,” says Mr. Harmon.

Healthcare systems like the U.S. Veterans Administration have also adopted sustained acoustic medicine to help patients dealing with soft tissue injury or chronic pain. For veterans of the United States military, as well as senior citizens, having access to the sam® device is a key part of their recovery. A nurse we will refer to as “Lori” in a very busy and influential VA pain management department uses the sam® device in place of opioids whenever possible. “The sam® device is the only thing in pain management that makes me feel like I am doing a great job for my patients,” Lori says. “It makes my patients feel much better.”

The sam® device can be used on any joint — even a patient’s hand — and reduces the risk of long-term NSAID use. “We have almost no issues with any of our patients using the device. We have treated younger patients and patients that are 85 years of age,” Lori says, noting the clinical efficiency of the device for both men and women. For older patients, the technology can seem daunting, so it is important to train patients on how to apply, charge, clean, and reuse the device before they receive treatment.

Lori instructs patients to never apply sustained acoustic medicine to the carotid arteries or their genitalia. Sometimes the area must be shaved for better coupling, but this step is not necessary for most patients. She also recommends applying sam® with a topical diclofenac just beyond the margins of pain. Once the diclofenac dries, the device can be placed over the painful spot. She instructs patients to follow this same process for four hours per day. “Our patients have excellent results on all types of arthritis of the knee and hand,” says Lori. “We also use the device a lot on muscle spasms and back injuries.”

A recent study determined that sam® reduces pain even in patients who have not responded to other types of physical therapy. Lori hopes that future research will focus on the clinical outcomes of using sam®, especially with challenging conditions like chronic regional pain syndrome and neuropathy. While affirmation from this research is important, George Lewis, President and CEO of ZetrOz Systems, as well as the inventor of sam®, notes that the clinical healing and pain relief the device provides to patients is what matters most.

Visit samrecover.com or zetrozsystems.com to learn more about this device and how it can support clinical outcomes within your organization or medical practice.

About ZetrOZ Systems
ZetrOZ Systems is an FDA cGMP and ISO 13585 medical technology company headquartered in the southern coastal region of Connecticut. The organization also has manufacturing facilities across the United States. ZetrOZ Systems produced UltrOZ®, sam®Sport and sam®Pro 2.0 to provide safe and effective treatment options for prevalent conditions such as arthritis. Learn more at zetroz.com and samrecover.com.

Media Contact:

Buse Kayar
buse@newswire.com
www.Newswire.com

Source: ZetrOZ Systems

Media Contacts:


Full Name
Company
Phone Number
Website
Email

Compose your email to at .


  Spam Protection

CROWN & ROOTS LAUNCHES SINGLE TOOTH IMPLANT TREATMENT AT AFFORDABLE COST

February 15, 2022 (Global News Distribution) -

Crown & Roots offered the single tooth implant treatment at affordable prices. This treatment uses an advanced procedure that takes up to 60 minutes to finish.

Crown & Roots, a top dental clinic in Delhi, India, offered a new dental implant surgery, the single tooth implant treatment. As the place with one of the most affordable Dental implant cost in Delhi, this new service excited many people who use this clinic service for years. The new single tooth implant treatment allows patients to save more money and get the implant in the place that they need. Furthermore, this clinic promised that the procedure would be painless and fast. For the single tooth implant surgery, it only requires 45-60 minutes to finish. Patients can return to their homes on the same day they visit this clinic to receive this treatment. This clinic, which is led by Dr. Kartik Datta, also offers natural looks, which is similar to the original tooth that the patient had before.

Crown & Roots offers various dental treatments for patients in India. The treatments cover various dental problems, from dental implants, braces, to cosmetic dentistry. This clinic has a team of the Best Dentist in Delhi. They have more than 20 years of experience in this industry. Moreover, they are all skilled and top dentists. Therefore, the result and treatment procedure produces the most satisfying result and receives positive feedback from its patients. This clinic also uses the latest technology and equipment, which provide better hygiene and safety for its treatment.

According to one of the doctors at Crown & Roots, Dr. Mansi Datta, “We provide the perfect solution for your missing tooth. Here, at Crown & Roots, we only use the highest quality dental implants. Moreover, they are also affordable. The dental implants we use have natural looks. It also has better durability and can last forever. Plus, we also ensure that we install it safely.” For more information about this treatment and Single tooth implant cost in Delhi, it is available at Crown & Roots’ official website.

About Crown & Roots

Crown & Roots offers various dental solutions in one building. With a team of experts and skilful doctors with more than 20 years of experience, the patients will get the most satisfying result from the treatment. This clinic has successfully fulfilled its mission to provide premium dental treatment for people from all economic classes.

Media Contact
Company Name: Crown & Roots Clinic
Contact Person: Dr. Kartik Datta
Phone: +91-9821999447
Address:L 1/3, Block-L, South Extension II
City: New Delhi
State: Delhi
Country: India
Website: https://www.crownandroots.com

Media Contacts:


Full Name
Company
Phone Number
Website
Email

Compose your email to at .


  Spam Protection

CROWN & ROOTS INTRODUCES TREATMENT FOR INSTALLING INVISIBLE BRACES

February 1, 2022 (Global News Distribution) -

Crown & Roots has launched the invisible braces treatment service. This treatment allows the patients to get teeth braces with better aesthetic and appearance than standard braces.

The braces now are not only a tool to fix one’s teeth condition. In India, the trend to have fashionable and beautiful braces that also can fix teeth problems is rising. Knowing that fact, Crown & Roots, the top Dental Clinic in Delhi, has offered a new brace treatment. It is called the invisible braces treatment or is also known as Invisalign. As its name implies, this new type of braces is made of clear plastic, so it is almost invisible after being installed on a patient’s teeth. It makes the brace look more fashionable.

Moreover, this clinic also provides the removable type one, making it easy to maintain. Moreover, this clinic also provides a maintenance and replacement service that patients can use once every two weeks. The cost is relatively the same as the standard Invisible braces cost in Delhi, which makes it more popular among the younger generation.

Crown & Roots is one of the reliable dental clinics in Delhi and India. This clinic provides various dental treatments. It is not only known as the top provider for Braces treatment in Delhi. This place also offers other treatments, such as root canal treatment, dental implant, teeth cleaning, and many more. The team of doctors in this clinic also has more than 20 years of experience. Plus, this clinic also prioritises hygiene every time providing treatment for its patients.

According to one of the staff of Crown & Roots, “Many people are afraid to visit the dental clinic because they think it will be painful. Many of them also have trauma after receiving that kind of treatment. In our clinic, we use a different approach for our dental treatment. We specialise in painless dental procedures that also provide the best result for our patients. And we are confident that we can do that because we have a skilled dentist who leads us, Dr. Kartik Datta.“

About Crown & Roots

Crown & Roots is a dental clinic in New Delhi, India, that provides complete treatment for different types of tooth problems and needs. It uses the latest technology and advanced procedures. It makes the patient feel more comfortable and relaxed when being treated. Dr. Kartik Datta is the man behind this clinic, known as the top dentist in India. This clinic has grown into one of the best dental clinics in Delhi and India.

Media Contact
Company Name: Crown & Roots Clinic
Contact Person: Dr. Kartik Datta
Phone: +91-9821999447
Address:L 1/3, Block-L, South Extension II
City: New Delhi
State: Delhi
Country: India
Website: https://www.crownandroots.com

Media Contacts:


Full Name
Company
Phone Number
Website
Email

Compose your email to at .


  Spam Protection

New book discusses a medical system that can help patients in the treatment of their illnesses

April 24, 2021 (Global News Distribution) -

Dr. Saran Zeb announces the release of ‘The Role of Homeopathy in the Patient’s Disease’

According to the National Health Service, homeopathy is a complementary or alternative medicine (CAM) based on a series of ideas developed in the 1790s by a German doctor named Samuel Hahnemann which means it is different from treatments that are part of conventional Western medicine in important ways.

In “The Role of Homeopathy in the Patient’s Disease” (published by AuthorHouse UK), Dr. Saran Zeb discusses this medical system and how it can help patients in the treatment of symptoms and illnesses. This book contains 18 chapters. The first chapter talks about the life of Dr. Samuel Hahnemann. The second chapter contains different methods of homeopathic treatment. In chapter three, Zeb discusses case taking. Chapter four contains a case analysis, chapter five consists of homeopathic repertorisation and chapter six discusses its minimum doses.

Chapter seven onward consists of various health issues and the cases which Zeb has treated for over 25 years. He also mentioned a few hundred cases in this book and the different types of methods. Each chapter is divided into three parts, therapeutic method, classical method and revolutionized method. In chapter 17, he mentioned accident and emergency remedies. Chapter 18 contains Materia Medica. He also includes 15 remedies, which can be used on a daily basis in homeopathic practice.

When asked what he wants readers to take away from this book, Zeb answers, “To give awareness about homeopathy. If conventional medicines does not help them, then they should not lose their hope. Homeopathy will help them.” For more details about this book, please visit https://www.authorhouse.com/en-gb/bookstore/bookdetails/820075-the-role-of-homeopathy-in-the-patients-disease.

“The Role of Homeopathy in the Patient’s Disease”
By Dr. Saran Zeb
Softcover | 6 x 9in | 462 pages | ISBN 9781665581011
E-Book | 462 pages | ISBN 9781665581028
Available at Amazon and Barnes & Noble

About the Author
Dr. Saran Zeb is a fully qualified, classically trained homoeopathic doctor and a member of the Faculty of Homeopathy. His homoeopathic qualifications include, DHMS, RHMP, HMD, LFHom, MFHom , PGCE. He has been practicing in the area of London for over 25 years. His achievements and services as a homeopathic doctor has been highly recognized and appreciated by the local community in London and its outskirt areas. Due to his success and reasonable demand in the East London area, he has to expand his services to reach out a greater number of people. He has treated over 5000 patients successfully who were under or on long-term care within the NHS primary and secondary care.

AuthorHouse, an Author Solutions, Inc. self-publishing imprint, is a leading provider of book publishing, marketing, and bookselling services for authors around the globe and offers the industry’s only suite of Hollywood book-to-film services. Committed to providing the highest level of customer service, AuthorHouse assigns each author personal publishing and marketing consultants who provide guidance throughout the process. Headquartered in Bloomington, Indiana, AuthorHouse celebrates over 23 years of service to authors.
For more information or to publish a book visit authorhouse.co.uk

Contact Author

MARKETING SERVICES
AuthorHouseUK
0-800-014-8641

Media Contacts:


Full Name
Company
Phone Number
Website
Email

Compose your email to at .


  Spam Protection

NuLife Helps Brick and Mortar Treatment Organizations Transition to Tech-Assisted Behavioral Health

April 14, 2021 (Global News Distribution) -

The company creates an opportunity for addiction treatment centers to increase care access, improve outcomes, deliver mobile-based counseling, therapy, coaching, and recovery support for patients, their family, and alumni.

NuLife Helps Brick and Mortar Treatment Organizations Transition to Tech-Assisted Behavioral Health in Hopes to Connect 1 Million Additional Individuals in Need of Effective Treatments for Addiction Amidst COVID-19 Pandemic and Beyond. For life!

The company creates an opportunity for addiction treatment centers to increase care access, improve outcomes, deliver mobile-based counseling, therapy, coaching, and recovery support for patients, their family, and alumni. 

  • The opioid crisis remains a serious public health threat across the U.S.;
  • By leveraging technology, NuLife Virtual is helping to ensure that effective treatment will be available to many more individuals struggling with addiction;
  • With a virtual experience, patients can remain connected to their treatment center, a therapist, and recovery communities while adhering to social distancing guidelines to prevent the spread of COVID-19.

Before the COVID-19 pandemic, NuLife was an industry leader for seven years in substance use disorder (SUD) treatment. At the end of 2019, it closed its brick-and-mortar operations. It transitioned to a fully digital B2B2C digital platform that partners with existing addiction treatment centers to extend its brand into virtual care services and expand access for millions of others who are battling addiction during this unprecedented crisis. 

NuLife, while still operating brick-and-mortar facilities, successfully used telemedicine to expand access to outpatient treatment for sober livings in Southern California and keep clients engaged outside of in-office visits.  

On January 15, 2020, the company decided to transition 100% of its clinical services onto its telemedicine platform. “After realizing the delivery of care online combined with an APP connecting people post-treatment not only worked, but people loved it, I decided to focus 100% on showing other treatment organizations how our model can help increase access to care and improve outcomes,” said JD Meints, Chief Executive Officer.

Addiction is often an isolating experience, and social connections are essential for sustainable recovery. But maintaining recovery communities is challenging with social distancing, as is the delivery of basic but powerful recovery capital needed to stay healthy in the best of times.

By developing a digital model that leverages multiple platforms—including secure, HIPAA-compliant voice, video, and SMS—NuLife Virtual is helping to ensure that effective treatment continues to be available to everyone who needs it. From California to Maine, patients can and will be using their mobile phones and the NuLife Virtual platform to meet and support one another through the challenges of addiction and, now, COVID-19.

“By leveraging technology, we can take an addiction treatment center virtual and ensure that patients remain connected to professionals, peers in recovery, even while physically separated,” says JD Meints, founder NuLife Virtual. 

“We founded NuLife Virtual to show those who struggle a way, a way to find help, a way to stay connected because I knew there was a way; they just need the right map,” said J.D. Meints. “Today, as the COVID-19 pandemic stresses our healthcare system, economy, and every aspect of daily life, it is up to us to create innovative solutions to save more lives. Our goal is to impact an additional 1 million lives with our platform.”

About NuLife Virtual

NuLife Virtual is a leader in delivering a social, mobile, digital health care platform. NuLife provides a uniquely effective tech-assisted behavioral health model that combines technology with evidence-based therapies, access to community professionals and peers, and holistic care content at the much of a button. What differentiates the NuLife Virtual model is the belief that long-term recovery from addiction is tied to aspects of life that are beyond the reach of traditional treatment models. They enhance reach by helping brick-and-mortar centers and their patients to form round-the-clock professional and peer community bonds, seek round-the-clock care and support, and address social determinants of health all in the virtual world right from the palm of their hand on an app.

NuLife Virtual will continue to lead industry innovations and ultimately will help change the world.

Media Contact

NuLife Virtual
community@nulifevirtual.com
818-797-97474774
Park Granada, Ste 8101
http://www.nulifevirtual.com

Source: https://nulifevirtual.com/

Media Contacts:


Full Name
Company
Phone Number
Website
Email

Compose your email to at .


  Spam Protection

Non-Pharmacological Treatment to Open New Growth Frontiers for Athletic Knee Treatment Market: Fact.MR

March 24, 2021 (Global News Distribution) -

Documented instance of side effects induced by orally consumed drugs is spurring approaches such as physiotherapy, bracing and transcutaneous electrical nerve stimulation

Fact.MR’s ongoing global athletic knee treatment market study projects a steady growth forecast through 2021, as the healthcare industry reorients its treatment priorities in the aftermath of the coronavirus pandemic. A further incline is anticipated, as public sports and athletic events resume in forthcoming years.

The National Safety Council (NSC), US, estimates that in 2019 alone, exercise with or without exercise equipment accounted for about 468,000 injuries. Bicycling followed with around 417,000 injuries, while basketball resulted in 404,000 incidents, and lastly football with 292,000 injuries. It estimated that most of these injuries resulted from unintended collisions between persons or with an object, mostly in the age group of 15 to 24 years.

Consequently, key manufacturers are augmenting their production capacities to accelerate drug development. Leading pharmaceutical provider Pfizer, for instance, is currently working on determining the effectiveness of its NCT02528188 (Tanezumab) candidate among knee and hip osteoarthritis patients. Besides, alternative approaches incorporating non-pharmacological approaches are also being investigated.

“Elevating concerns over possible side-effects of orally administered drugs is spurring drives for alternative treatment approaches, mostly reliant on non-pharmacological options, prompting manufacturers to develop advance knee pain management solutions,” says the Fact.MR analyst.

Request a report sample to gain comprehensive insights at https://www.factmr.com/connectus/sample?flag=S&rep_id=3883

Key Takeaways from Fact.MR’s Athletic Knee Treatment Market Study

  • By drug class, corticosteroids to remain the preferred treatment option due to provision of instant pain relief
  • High preference for oral administration to remain, topical administration witnessing significant incline
  • Hospitals to remain primary athletic knee treatment drug procurers, attributed to high preference for hospital-grade treatment
  • US to emerge as a lucrative market, attributed to rising incidences of knee injuries amid rising football popularity
  • Treatment for anterior cruciate ligament (ACL) primarily stimulating demand across the UK
  • Germany & France to provide a wide expansion ground for anti-inflammatory athletic knee treatment drug sales
  • Increasing efforts to promote stem-cell based treatment widening growth prospects for India
  • China to remain a prominent market, providing a combination of traditional and modern medicinal treatments

Athletic Knee Treatment Market- Prominent Drivers

  • Growing emphasis on sports is increasing knee injury incidences, providing stimulus to athletic knee treatment product sales
  • Alternative approaches, including transcutaneous electrical nerve stimulation (TENS), are acquiring immense popularity
  • Investment in preventive genomics to ascertain knee injury susceptibility to play an instrumental role in accelerating treatment prospects

Athletic Knee Treatment- Key Restraints

  • Inadequate awareness about prominent causes for athletic knee pain onset to restrain treatment uptake
  • A shift towards non-pharmacological pain management is likely to limit uptake of athletic knee treatment drugs in the future

Discover more about the athletic knee treatment market with figures, data tables and the table of contents. You will also find detailed market segmentation on https://www.factmr.com/report/3883/athletic-knee-treatment-market

Competitive Landscape

F. Hoffmann-La Roche AG, Ferring BV, Merck & Co. Inc., Johnson & Johnson, Amgen Inc. and Pfizer Inc. are some prominent athletic knee treatment products manufacturers profiled by Fact.MR in its study. Aforementioned players largely rely on developing new drug formulations, besides engaging in capacity expansion measures including collaborations and acquisitions.

Ferring BV, a prominent pharmaceutical giant, manufactures the EUFLEXXA (1% sodium hyaluronate) hyaluronic acid for injection purposes. The drug is injected into the knees of osteoarthritis sufferers to improve movement and reduce pain. Helping cushion, lubricate and protect the knee during its movement, the drug helps alleviate short-term pains experienced during strenuous athletic activities as well.

Besides drugs, numerous knee replacement solutions are also offered by some players, in case of severe injuries. Johnson & Johnson medical, for instance, offers the ATTUNE® Knee System, a state-of-the-art knee replacement system, consisting of the ATTUNE GRADIUSTM Curve to facilitate smooth motion and stability, the GLIDERIGHTTM Articulation to optimize kneecap movement, and the AOXTM Antioxidant Polyethylene plastic wedge to replace the cartilage.

More Insights on the Athletic Knee Treatment Market

In its latest report, Fact.MR offers unbiased analysis of the global athletic knee treatment market. In order to understand the global market potential, its growth, and scope, the market is segmented on the basis of drug class (corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDS) and hyaluronic acid), route of administration (topical, oral and intramuscular) and end user (hospitals, clinics, and ambulatory surgical centers) across seven regions (North America, Latin America, Europe, CIS & Russia, Japan, APEJ and Middle East & Africa)

Request for No-Obligation Table of Content

https://www.factmr.com/connectus/sample?flag=T&rep_id=3883

Explore Fact.MR’s Coverage on the Healthcare Domain

Lab Automation Market: A recent study by Fact.MR on the lab automation market offers a 10-year forecast for 2021 to 2031. The study analyzes crucial trends that are currently determining the growth of the market. This report explicates on vital dynamics, such as the drivers, restraints, and opportunities for key market players along with key stakeholders.

Assistive Technologies Demand for Visually Impaired Market: A study by Fact.MR on the assistive technologies demand for visually impaired market offers a long-term forecast, explicating on the key expansion drivers expected to shape demand. Prominent drivers, trends and opportunities in key segments across prominent geographies have been mapped in the report, along with an in-depth competitive landscape.

Antacids Market: The antacids market report is a study on the current scenario, on end user’s requirements, new developments, and the issues faced by the supply chain as a whole in the landscape. It is meant to provide readers with an exclusive view of the antacids market as a whole, and a detailed understanding of the major players in the antacids landscape.

About Fact.MR

Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. We have offices in US and Dublin, whereas our global headquarter is in Dubai. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Reach out to us with your goals, and we’ll be an able research partner.

Contact:

US Sales Office:

11140 Rockville Pike

Suite 400

Rockville, MD 20852

United States

Tel: +1 (628) 251-1583

E: sales@factmr.com

Follow Us: LinkedIn | Twitter

Market Intelligence Services: Marketngage.com

SOURCE: Fact.MR

Media Contacts:


Full Name
Company
Phone Number
Website
Email

Compose your email to at .


  Spam Protection

World Hearing Day – Amplifon Confirms Commitment to Ongoing Prevention & Treatment of Hearing Loss

March 2, 2021 (Global News Distribution) -

Amplifon is proud to celebrate World Hearing Day, confirming its commitment to the treatment and prevention of hearing loss, a condition that impacts nearly 40 million Americans.

According to new research from the World Health Organization, by 2050, the number of individuals who will be living with some degree of hearing loss is set to reach 2.5 billion. As such, identification and treatment have never been more important, especially considering almost 60 percent of hearing loss in children is due to causes that can be mitigated through preventative measures.

For this reason, Amplifon is committed to promoting the importance of prevention and proper education on responsible listening and is incredibly proud of the work of our Miracle-Ear Foundation, which provides adults and children free hearing aids and a lifetime of qualifying services at no cost. Since its founding in 1990, the Miracle-Ear Foundation has donated more than 30,000 hearing aids to more than 16,000 children and adults nationwide, who would otherwise not be able to afford them.

The difficulties for those suffering from hearing loss increased in 2020, with the start and ongoing spread of COVID-19. The pandemic brought increased attention to the importance of hearing in remaining connected with friends and families, with the necessary use of face masks making communication more challenging for those suffering from hearing loss.

To ensure our communities had ongoing access to essential hearing care services in our Miracle-Ear stores, Amplifon developed a new operative model in collaboration with internationally renowned experts from the Columbia University College of Physicians and Surgeons to implement rigorous protocols and safety standards in our stores.

“Untreated hearing loss has been linked to many serious conditions, including depression, dementia and Alzheimer’s, but getting your hearing checked is a critical first step in the process,” says Carrie Meyer, Au.D., Director of Clinical Programs for Amplifon Americas. “Effective and timely interventions can benefit those at risk of, or living with, hearing loss. Simply put, prevention and treatment are the keys to living a healthier, fuller life.”

Despite the ongoing and real challenges presented in this latest research, Amplifon is committed to continuing to make an impact in the lives of those with hearing loss and driving ongoing awareness about this issue. Click the links that follow for additional information about Amplifon or the World Health Organization.

About Amplifon Americas

Amplifon Americas, a division of Amplifon Group, is a leading provider of hearing health care solutions in the U.S. and Canada. Headquartered in downtown Minneapolis, Minnesota, Amplifon Americas is a multi-year Top Workplace award winner, and its team of 850 people is dedicated to serving the diverse needs of its customers through four unique and independent brands: Miracle-Ear, Elite Hearing Network, Amplifon Hearing Health Care and Amplifon Canada.

Contacts

Communication Contact
Chad Eldred
M. +1 (320) 333-4749
Chad.Eldred@amplifon.com

Media Contacts:


Full Name
Company
Phone Number
Website
Email

Compose your email to at .


  Spam Protection

HOW TO MANAGE ANXIETY AND DEPRESSION DUE TO COVID-19 IN 2021

February 12, 2021 (Global News Distribution) -

Nearly half of college students, many stuck at home or in their dorms taking classes mostly online, screened positive for symptoms of depression or anxiety in the fall, according to a new national survey.

Nearly half of college students, many stuck at home or in their dorms taking classes mostly online, screened positive for symptoms of depression or anxiety in the fall, according to a new national survey. The prevalence of mental health distress was up slightly from the 44% found last school year.

The Healthy Minds Study surveyed 33,000 students at 36 colleges last fall and found that 47% showed signs of depression, anxiety or both on a standard questionnaire. More than eight in 10 students said their mental health has negatively affected their academic performance on at least one day.

Sarah Lipson, a public health professor at Boston University who co-authored the study, said the negative impact on academics was the highest rate since the annual surveys began in 2007.

“Memory, concentration — those things are really being tested and pulled, and we’re at a deficit for our ability to focus,” said Lipson, who finds many of her students are exhausted and struggling with sleep just days into this new semester.

She attributed the increased anxiety to “the burnout and monotony of what we’ve been doing for nearly a year now,” citing “what this has actually done to our brains and our neural pathways.”

For the first time, the survey asked students about loneliness. Two-thirds said they feel isolated from others sometimes or often.

Among students with a positive screen for depression or anxiety, just 40% said they had received any mental health counseling or therapy in the past year. The study said that the “treatment gap” was wider than in previous semesters, but not by a large margin.

Essential Habits To Prevent Anxiety & Depression

Sleep More to Manage Anxiety and Stress

Get enough sleep. A lack of sleep can increase anxiety and stress and give anxious thoughts and feelings, so try to get about seven to nine hours of quality sleep a night. Try to cut off late-night screen time to at least 30 minutes before bedtime. Cut off caffeine 8-10 hours before rest and make your room as dark as possible.

Exercise to Manage Anxiety and Stress

This is not news; exercise is excellent to fight stress! According to the Anxiety and Depression of America, studies report found that regular cardio exercise has decreased overall stress levels and tension, elevates and stabilizes mood, improves sleep, and improves self-esteem.

Diet to Manage Anxiety and Stress

Having a healthy diet with all of the right foods and vitamins is an excellent place to start to prevent anxiety. Studies suggest that eating foods rich in omega-3 acids can reduce stress. Foods high in prebiotics are chicory root, dandelion greens, Jerusalem artichoke, garlic, onions, asparagus, bananas, leeks, oats, and barley. Antianxiety supplements are becoming popular as well. After taking antianxiety supplements, subjects were less anxious when given negative information.

Meditation to Manage Anxiety and Stress

Media Contact
Company Name: Nebula
Contact Person: Clark K.
Email: Send Email
Phone: +15034775799
Address:11605 SE Powell BLVD
City: Portland
State: OR 97266
Country: United States
Website: https://www.nebulapdx.com/

Media Contacts:


Full Name
Company
Phone Number
Website
Email

Compose your email to at .


  Spam Protection

Sunshine Biopharma Initiates COVID-19 Treatment Mice Study

February 10, 2021 (Global News Distribution) -

Sunshine Biopharma Inc. (OTC PINK:SBFM), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today announced that it has initiated a momentous transgenic mice study of its COVID-19 treatment that has been under development since May of last year. Sunshine Biopharma’s COVID-19 treatment consists of a series of small molecules which suppress replication of the virus by inhibiting a key virus encoded protease that is responsible for compromising the immune system of infected patients. The mice studies are currently underway at the University of Georgia, College of Pharmacy.

The mice being used in the study have been genetically engineered to express the human angiotensin-converting enzyme 2 (hACE2) transmembrane protein in their lungs making them susceptible to lethal infection by SARS-CoV-2, the causative agent of COVID-19. The SARS-CoV-2 virus uses the hACE2 receptor to gain entry into human cells to replicate. The goal of the study is to determine if Sunshine Biopharma’s protease inhibitors will protect the hACE2-transgenic mice from disease progression and death following infection with SARS-CoV-2 virus.

“Should these mice studies prove successful, we plan to submit the results to the FDA for authorization to conduct testing on actual COVID-19 patient volunteers in a Phase I clinical trial setting,” said Dr. Steve Slilaty, CEO of Sunshine Biopharma. “We are excited to have initiated this pivotal study on transgenic mice with the University of Georgia. The implications of a COVID-19 treatment becoming available are vast. This is particularly the case in view of the fact that some of the variants emerging around the world are more virulent and may escape neutralization by the current vaccines,” he added.

About Sunshine Biopharma’s Coronavirus Treatment
Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) is the etiologic agent of the ongoing COVID-19 pandemic that has claimed the lives of over 2.3 million people worldwide since it first appeared in December 2019. There are currently no drugs that can effectively arrest replication of the virus in people who have contracted the illness. On May 22, 2020, Sunshine Biopharma filed a provisional patent application for several molecules which were designed by computer-aided modeling to inhibit the Coronavirus proteases, thus shutting down the ability of the virus to multiply. Sunshine Biopharma has since completed the synthesis of four such molecules and identified a lead compound, SBFM-PL4. In collaboration with the University of Georgia, College of Pharmacy, the Company is currently advancing the development of SBFM-PL4 through the in vitro testing stage to be followed by mice studies, currently underway, before entering clinical trials on COVID-19 patients.

About Sunshine Biopharma
In addition, to working on the development of a treatment for COVID-19, Sunshine Biopharma is engaged in the development Adva-27a, a unique anticancer compound. Tests conducted to date have demonstrated the effectiveness of Adva-27a at destroying Multidrug Resistant Cancer Cells, including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells, and Uterine Sarcoma cells. Clinical trials for Pancreatic Cancer indication are planned to be conducted at McGill University’s Jewish General Hospital in Montreal, Canada. Sunshine Biopharma is owner of all patents and intellectual property pertaining to Adva-27a.

Safe Harbor Forward-Looking Statements
This press release may contain forward looking statements which are based on current expectations, forecasts, and assumptions that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially from those anticipated or expected, including statements related to the amount and timing of expected revenues statements related to our financial performance, expected income, distributions, and future growth for upcoming quarterly and annual periods. These risks and uncertainties are further defined in filings and reports by the Company with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain events could differ materially from those projected in or contemplated by the forward-looking statements due to a number of factors detailed from time to time in our filings with the SEC. Among other matters, the Company may not be able to sustain growth or achieve profitability based upon many factors including but not limited to general stock market conditions. Reference is hereby made to cautionary statements set forth in the Company’s most recent SEC filings. We have incurred and will continue to incur significant expenses in our expansion of our existing as well as new service lines noting there is no assurance that we will generate enough revenues to offset those costs in both the near and long term. Additional service offerings may expose us to additional legal and regulatory costs and unknown exposure(s) based upon the various geopolitical locations we will be providing services in, the impact of which cannot be predicted at this time.

For Additional Information Contact:
Camille Sebaaly, CFO
Sunshine Biopharma Inc.
Direct Line: 514-814-0464
camille.sebaaly@sunshinebiopharma.com
www.sunshinebiopharma.com

SOURCE: Sunshine Biopharma Inc.

Media Contacts:


Full Name
Company
Phone Number
Website
Email

Compose your email to at .


  Spam Protection

Scientists Find Compound to Create Treatment Regimen for COVID-19

February 8, 2021 (Global News Distribution) -

A team of scientists at Atakam Medical are pleased to announce they have found a compound that may help to create an effective treatment regimen for those suffering from COVID-19.

Atakam Medical is a research company that develops bio-active compounds as candidates for creating novel therapies. Founded in 1990 by President Andrew Osichnuk, the company is an international team with a strong scientific background. Its core members include Anatolii Demchenko, Chief Scientific Officer, Eugene Stavtsev, Chief Executive Officer, Valery Polyakov, Corporate Attorney, and Oleksiy Khozyainov, Chief Information Officer.

In the company’s most recent news, the team at Atakam Medical have developed and patented a line of bioactive compounds that have shown a very strong antiviral activity towards SARS-CoV-2. These compounds destroy the coronavirus inhibitor (virus SARS-CoV-2) and screening of the active compounds have been conducted in collaboration with Southern Research in Birmingham, Alabama. Through this screening, Atakam Medical discovered these compounds are non-toxic for the living cell of an organism, confirming that scientists can create effective regiments for the treatment of COVID-19.

“As we know, the global pandemic is spreading rapidly with more than 101.5 million people contracting the disease and 2.19 million patients dying as a result,” says Osichnuk. “While scientists are working hard to develop and roll out vaccines, there have not been any drugs that show critical effectiveness in treating the virus. Today, we are announcing that this has changed.”

Atakam Medical’s patented line of bioactive compounds not only show strong effectiveness in treating SARS-CoV-2, but the company also has research data which shows these compounds are equally as effective against all three types of coronaviruses, including SARS-CoV, MERS-CoV, and SARS-CoV-2.
“We can attribute the effectiveness of the compounds to their unique mechanism of action, which can also be effective against other strains of SARS-CoV-2,” Osichnuk continues. “Because of this, the pharmacological effects of the future therapies based on these compounds will not depend on the virus mutation. Since our COVID-19 antiviral compounds have extremely low, nanomolar weight, it presents us with an excellent opportunity to create an inhalant with rapid delivery of our medicine, straight to the lungs. The SARS-CoV-2 virus is not a predicament to mankind – it is merely an RNA molecule we have already defeated.”

With this announcement, Atakam Medical welcomes pharmaceutical, biotechnology companies, investors, and other interested parties for collaboration to create new therapies against COVID-19.

For more information about Atakam Medical, please visit www.atakamed.com.

About Atakam Medical

Atakam Medical was founded in 1990 by Andrew Osichnuk, a successful entrepreneur who holds a master’s degree in Philosophy and Applied Mathematics in Computer Science. In addition to creating Atakam Medical, Osichnuk is also the original founder and former Vice President of Central European Bank.

Andrew Osichnuk
Atakam Medical
+1 307-776-9333
office@atakamed.com

Media Contacts:


Full Name
Company
Phone Number
Website
Email

Compose your email to at .


  Spam Protection